Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Uhlik

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|October 31, 2017
An Endothelial Cell/Mesenchymal Stem Cell Coculture Cord Formation Assay to Model Vascular Biology In VitroMichelle Swearingen, Beverly Falcon, Sudhakar Chintharlapalli, et al.
Journal of Biomolecular Screening|February 8, 2011
A quantitative, facile, and high-throughput image-based cell migration method is a robust alternative to the scratch assayWendy Gough, Keren I Hulkower, Renee Lynch, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated OutcomesPanagiotis Ntellas, Haeseong Park, Kerry Culm, et al.
Oncology|December 7, 2023
RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and NivolumabRuoyu Miao, Dae Won Kim, James Yu, et al.
Plos One|September 12, 2014
An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factorsBeverly L Falcon, Michelle Swearingen, Wendy H Gough, et al.
Molecular Cancer Therapeutics|December 23, 2011
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesisGiulio Francia, Yuval Shaked, Kae Hashimoto, et al.
Frontiers in Oncology|May 30, 2023
Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancersMark Uhlik, Daniel Pointing, Seema Iyer, et al.
Nature Communications|October 10, 2023
Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in miceStacy K Thomas, Max M Wattenberg, Shaanti Choi-Bose, et al.
Molecular Cancer Therapeutics|September 10, 2011
Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalizationTimothy Meier, Mark Uhlik, Sudhakar Chintharlapalli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2025
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapyAlison T Stopeck, Maysa Abu-Khalaf, Virginia Borges, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|October 31, 2017
An Endothelial Cell/Mesenchymal Stem Cell Coculture Cord Formation Assay to Model Vascular Biology In VitroMichelle Swearingen, Beverly Falcon, Sudhakar Chintharlapalli, et al.
Journal of Biomolecular Screening|February 8, 2011
A quantitative, facile, and high-throughput image-based cell migration method is a robust alternative to the scratch assayWendy Gough, Keren I Hulkower, Renee Lynch, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated OutcomesPanagiotis Ntellas, Haeseong Park, Kerry Culm, et al.
Oncology|December 7, 2023
RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and NivolumabRuoyu Miao, Dae Won Kim, James Yu, et al.
Plos One|September 12, 2014
An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factorsBeverly L Falcon, Michelle Swearingen, Wendy H Gough, et al.
Molecular Cancer Therapeutics|December 23, 2011
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesisGiulio Francia, Yuval Shaked, Kae Hashimoto, et al.
Frontiers in Oncology|May 30, 2023
Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancersMark Uhlik, Daniel Pointing, Seema Iyer, et al.
Nature Communications|October 10, 2023
Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in miceStacy K Thomas, Max M Wattenberg, Shaanti Choi-Bose, et al.
Molecular Cancer Therapeutics|September 10, 2011
Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalizationTimothy Meier, Mark Uhlik, Sudhakar Chintharlapalli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2025
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapyAlison T Stopeck, Maysa Abu-Khalaf, Virginia Borges, et al.
Pageof 2